pyrazines has been researched along with Cancer of Gastrointestinal Tract in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bendell, J; de Haan, H; Filvaroff, EH; Hege, K; Li, S; Mahipal, A; Meyer, T; Mita, A; Mita, M; Munster, PN; Nemunaitis, J; Paz-Ares, L; Wolin, E | 1 |
| Abbott, A; Belinsky, M; Chugh, R; Crowley, J; Flieder, DB; George, S; Heinrich, MC; Hornick, JL; Janeway, KA; Litwin, S; Rink, L; Schuetze, SM; Van den Abbeele, AD; von Mehren, M; Yap, JT; Yu, JQ | 1 |
| Alinari, L; Bond, DA; Maddocks, K | 1 |
| Eatock, MM; Gallagher, R; James, CR; Law, D; Millar, J; Morris, M; Napier, E; Purcell, C; Turkington, RC; Wilson, RH | 1 |
| Beric, A; Hochster, H; Ivy, P; Joseph, SO; Kobrinsky, B; Liebes, L; Malankar, A; Muggia, F | 1 |
| Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF | 1 |
| Adachi, M; Hinoda, Y; Imai, K; Kawamura, R; Minami, T; Zhang, Y; Zhao, X | 1 |
| Chrysanthopoulou, H; Dimopoulos, MA; Kastritis, E; Matsouka, C; Michopoulos, S; Petraki, K | 1 |
1 review(s) available for pyrazines and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Forecasting; Gastrointestinal Neoplasms; Hemorrhage; Humans; Immunologic Factors; Lymphocytosis; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Neoplasm Proteins; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Salvage Therapy | 2019 |
5 trial(s) available for pyrazines and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.
Topics: Administration, Oral; Adult; Aged; Carcinoid Tumor; Cohort Studies; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Middle Aged; Neuroendocrine Tumors; Pyrazines | 2019 |
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
Topics: Adolescent; Adult; Electron Transport Complex II; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imidazoles; Male; Middle Aged; Mutation; Patient Safety; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazines; Receptor, IGF Type 1; Treatment Outcome; Young Adult | 2020 |
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Deoxycytidine; Epirubicin; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Proteasome Inhibitors; Pyrazines | 2014 |
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Tumor Burden | 2013 |
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2012 |
2 other study(ies) available for pyrazines and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Topics: Adenocarcinoma; Annexin A5; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line, Tumor; Cinnamates; Colonic Neoplasms; Depsipeptides; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Free Radicals; Gastrointestinal Neoplasms; Histones; Humans; Microscopy, Confocal; Oligopeptides; Oxygen; Phosphorylation; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Time Factors | 2004 |
Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Immunohistochemistry; Lymphoma, Mantle-Cell; Male; Prednisone; Prognosis; Pyrazines; Rituximab; Severity of Illness Index; Treatment Outcome; Vincristine | 2008 |